Hepatology News

After an historic rate hike cycle that was the fastest on record and largest in decades, the Federal Reserve announced its first rate cut since 2020 this past September.

Physicians employed under W-2 status are often presented with a variety of employer-sponsored benefit plans, which can provide significant tax and financial advantages.

The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.

Data from a postlicensure study support the CDC’s recommendation that Heplisav-B can now be administered to pregnant persons needing hepatitis B vaccination, as its use did not appear to increase risk for major birth defects or miscarriage.

The FDA granted fast track designation to Lipocine’s LPCN 1148, an oral androgen receptor agonist containing testosterone dodecanoate, for the treatment of sarcopenia in patients with decompensated cirrhosis, according to the manufacturer.

Investing, compound interest, dollar-cost averaging — these concepts seem more mathematical than mental.

The FDA has issued a safety alert warning that obeticholic acid carries an increased risk for “serious liver injury” among patients with primary biliary cholangitis, even those without advanced cirrhosis.

Older age but not high comorbidity burden was significantly associated with overall survival among patients with hepatocellular carcinoma, even those with early-stage disease, according to study results.

Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.